Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2361]

Multiplex IHC as biomarkers for cancer immunotherapy

Dr Paul Tumeh - UCLA Medical Center, Los Angeles, USA

Multiplex IHC as biomarkers for cancer immunotherapy ( Dr Paul Tumeh - UCLA Medical Center, Los Angeles, USA )

Direct activation of STING in the tumour microenvironment leads to potent and...

Dr Thomas Dubensky - Aduro Biotech, Berkley, USA

Direct activation of STING in the tumour microenvironment leads to potent and systemic tumour regression and immunity ( Dr Thomas Dubensky - Aduro Biotech, Berkley, USA )

Understanding personalised medicine - the e-learning course

Prof Gordon McVie

Understanding personalised medicine - the e-learning course ( Prof Gordon McVie )

Mechanisms of immune escape in non-Hodgkin lymphoma

Dr Riccardo Dalla-Favera - Columbia University Medical Center, New York, USA

Mechanisms of immune escape in non-Hodgkin lymphoma ( Dr Riccardo Dalla-Favera - Columbia University Medical Center, New York, USA )

'Helper' T Cells effective in therapy, and shows early clinical responses in...

Dr Yong-Chen William Lu - National Cancer Institute, Bethesda, USA

'Helper' T Cells effective in therapy, and shows early clinical responses in patients with metastatic cancer ( Dr Yong-Chen William Lu - National Cancer Institute, Bethesda, USA )

Innovations in assessing patient outcomes

Dr Heather Jim - Moffitt Cancer Center, Tampa, USA

Innovations in assessing patient outcomes ( Dr Heather Jim - Moffitt Cancer Center, Tampa, USA )

Repopulation of cancer stem cells in therapeutic resistance

Prof Keith Chan - Baylor College of Medicine, Houston, USA

Repopulation of cancer stem cells in therapeutic resistance ( Prof Keith Chan - Baylor College of Medicine, Houston, USA )

Technologies for personalised cancer immunotherapies

Prof James Heath - California Institute of Technology, Pasadena, USA

Technologies for personalised cancer immunotherapies ( Prof James Heath - California Institute of Technology, Pasadena, USA )

Comment on RESONATE2 and CLL115 trials

Dr Peter Hillmen - Leeds Teaching Hospitals NHS Trust, Leeds, UK

Comment on RESONATE2 and CLL115 trials ( Dr Peter Hillmen - Leeds Teaching Hospitals NHS Trust, Leeds, UK )

Microenvironment of chronic lymphocytic leukaemia

Dr George Follows, Cambridge University Hospitals NHS Foundation Trust...

Microenvironment of chronic lymphocytic leukaemia ( Dr George Follows, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK )

Chronic lymphocytic leukaemia: Transition to a new era

Prof Stephen Mulligan - Royal North Shore Hospital, Australia

Chronic lymphocytic leukaemia: Transition to a new era ( Prof Stephen Mulligan - Royal North Shore Hospital, Australia )

Drugging “undruggable” transcription factor drivers in cancer

Dr John Bushweller - Unviersity of Virgina, Virginia, USA

Drugging “undruggable” transcription factor drivers in cancer ( Dr John Bushweller - Unviersity of Virgina, Virginia, USA )

More from ecancer